Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Viridian Therapeutics, Inc. (VRDN) Tops Q3 EPS by 16c
November 13, 2023 4:05 PM ESTViridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($1.09), $0.16 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $72 thousand versus the consensus estimate of $141.08 thousand.
For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.
... More